Literature DB >> 27752833

Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Yoshiki Asayama1, Akihiro Nishie2, Kousei Ishigami2, Yasuhiro Ushijima2, Yukihisa Takayama2, Daisuke Okamoto2, Nobuhiro Fujita2, Takao Ohtsuka3, Tomoharu Yoshizumi4, Shinichi Aishima5,6, Yoshinao Oda6, Hiroshi Honda2.   

Abstract

OBJECTIVES: To determine whether washout characteristics of dynamic contrast-enhanced computed tomography (CT) could predict survival in patients with extrahepatic cholangiocarcinoma (EHC).
METHODS: This study collected 46 resected cases. All cases were examined by dynamic contrast study on multidetector-row CT. Region-of-interest measurements were obtained at the non-enhanced, portal venous phase and delayed phase in the tumour and were used to calculate the washout ratio as follows: [(attenuation value at portal venous phase CT - attenuation value at delayed enhanced CT)/(attenuation value at portal venous phase CT - attenuation value at unenhanced CT)] × 100. On the basis of the median washout ratio, we classified the cases into two groups, a high-washout group and low-washout group. Associations between overall survival and various factors including washout rates were analysed.
RESULTS: The median washout ratio was 29.4 %. Univariate analysis revealed that a lower washout ratio, venous invasion, lymphatic permeation and lymph node metastasis were associated with shorter survival. Multivariate analysis identified the lower washout ratio as an independent prognostic factor (hazard ratio, 3.768; p value, 0.027).
CONCLUSIONS: The washout ratio obtained from the contrast-enhanced CT may be a useful imaging biomarker for the prediction of survival of patients with EHC. KEY POINTS: • Dynamic contrast study can evaluate the aggressiveness of extrahepatic cholangiocarcinoma. • A lower washout ratio was an independent prognostic factor for overall survival. • CT can predict survival and inform decisions on surgical options or chemotherapy.

Entities:  

Keywords:  Contrast enhancement pattern; Extrahepatic cholangiocarcinoma; Multidetector computed tomography; Pathology; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27752833     DOI: 10.1007/s00330-016-4621-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

Review 1.  Adrenal imaging: why, when, what, and how? Part 2. What technique?

Authors:  Giles W L Boland
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

2.  Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Kengo Yoshimitsu; Hiroyuki Irie; Tsuyoshi Tajima; Akihiro Nishie; Masakazu Hirakawa; Tomohiro Nakayama; Daisuke Kakihara; Akinobu Taketomi; Shin-ichi Aishima; Hiroshi Honda
Journal:  Radiology       Date:  2005-11-22       Impact factor: 11.105

3.  Pathological manifestation of difference in washout pattern of adrenal hyperplasia on dynamic CT.

Authors:  Akihiro Nishie; Yoshiki Asayama; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Yasuhiro Ushijima; Yukihisa Takayama; Akira Yokomizo; Katsunori Tatsugami; Junichi Inokuchi; Nobuhiro Fujita; Yuichiro Kubo; Shinichi Aishima; Masakazu Hirakawa; Hiroshi Honda
Journal:  J Med Imaging Radiat Oncol       Date:  2014-07-17       Impact factor: 1.735

Review 4.  Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.

Authors:  Shinichi Aishima; Yoshinao Oda
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-02       Impact factor: 7.027

5.  Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Takeshi Muto; Hayato Sasaki; Kazuhide Urabe; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

Review 6.  Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition.

Authors:  Masaru Miyazaki; Masayuki Ohtsuka; Shuichi Miyakawa; Masato Nagino; Masakazu Yamamoto; Norihiro Kokudo; Keiji Sano; Itaru Endo; Michiaki Unno; Kazuo Chijiiwa; Akihiko Horiguchi; Hisafumi Kinoshita; Masaaki Oka; Keiichi Kubota; Masanori Sugiyama; Shinji Uemoto; Mitsuo Shimada; Yasuyuki Suzuki; Kazuo Inui; Susumu Tazuma; Junji Furuse; Akio Yanagisawa; Yasuni Nakanuma; Hiroshi Kijima; Tadahiro Takada
Journal:  J Hepatobiliary Pancreat Sci       Date:  2015-02-17       Impact factor: 7.027

7.  Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?

Authors:  G Ercolani; A Dazzi; F Giovinazzo; A Ruzzenente; C Bassi; A Guglielmi; A Scarpa; A D'Errico; A D Pinna
Journal:  Eur J Surg Oncol       Date:  2015-06-10       Impact factor: 4.424

8.  Cholangiocarcinoma: delayed CT contrast enhancement patterns.

Authors:  J M Lacomis; R L Baron; J H Oliver; M A Nalesnik; M P Federle
Journal:  Radiology       Date:  1997-04       Impact factor: 11.105

9.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

10.  Enhancement characteristics of cholangiocarcinomas on mutiphasic helical CT: emphasis on morphologic subtypes.

Authors:  Na Ra Kim; Jeong Min Lee; Se Hyung Kim; Su Kyung An; Chang Jin Han; Seung Hong Choi; Joon Koo Han; Hye Seung Lee; Ja Jun Jang; Byung Ihn Choi
Journal:  Clin Imaging       Date:  2008 Mar-Apr       Impact factor: 1.605

View more
  1 in total

1.  Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma.

Authors:  Yong Tang; Chun Mei Yang; Song Su; Wei Jia Wang; Li Ping Fan; Jian Shu
Journal:  BMC Cancer       Date:  2021-11-24       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.